Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsPreferred Shares RepurchasedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Cash from Operations (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Cash from Operations for 17 consecutive years, with 786848.0 as the latest value for Q1 2026.

  • Quarterly Cash from Operations fell 54.32% to 786848.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 4800723.0 through Jan 2026, down 111.4% year-over-year, with the annual reading at 2978296.0 for FY2025, 38.43% down from the prior year.
  • Cash from Operations for Q1 2026 was 786848.0 at PharmaCyte Biotech, up from 979523.0 in the prior quarter.
  • The five-year high for Cash from Operations was 342959.0 in Q3 2023, with the low at 1993981.0 in Q3 2025.
  • Average Cash from Operations over 5 years is 833783.59, with a median of 786848.0 recorded in 2026.
  • The sharpest move saw Cash from Operations soared 131.63% in 2023, then plummeted 434.15% in 2025.
  • Over 5 years, Cash from Operations stood at 1879264.0 in 2022, then fell by 5.59% to 1984354.0 in 2023, then soared by 46.85% to 1054735.0 in 2024, then increased by 7.13% to 979523.0 in 2025, then rose by 19.67% to 786848.0 in 2026.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 786848.0, 979523.0, and 1993981.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.